Breast cancer and hormonal contraceptives : collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies

Año de publicación

1996

UUID

5522071a-43f5-484d-89e4-df8b309b74de

Resumen

The use of female sex hormones as contraceptives began in 1960, since when an estimated 200 million women throughout the world have used them.1 The most widely used type of hormonal contraceptive has been the combined oral contraceptive, which contains an oestrogen and progestagen and is prepared from various compounds in various doses and combinations. Other hormonal contraceptives contain progestagen only, given orally or by injection. Many epidemiological studies have investigated whether hormonal contraceptives might affect breast cancer risk,2 K and the Collaborative Group on Hormonal Factors in Breast Cancer was set up in 1992 to bring together, reanalyse, and publish the worldwide data. The main results are summarised here. Additional results, together with full descriptions of the methods, the studies and the women included, are being published elsewhere.

Publicador

The Lancet, Vol. 347, no. 9017

Enlace del origen de la publicación

Documentación restringida

No

Tipo de publicación

Article

Descriptores

• ENFERMEDADES
• CANCER
• ANTICONCEPTIVOS